Reason for request
Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient. |
eNq1mFFv2jAQx9/5FFHeSRpoVzYFqo21G1KrMVq0aS/IJEcxc+30bAPdp59D6EYnRx0GP/BAbP/v4vv751PSi/UDC5aAkgreDZPoJAyAZyKn/L4bju+ump3wotdIF2RJdqadRydR0gqDjBEpu2E5Gk2BcBl9v7n+CGY9YNhrBKmYLiBTL+ZpRVn0mcj5DSnKOUG6FDQPHkDNRd4NC602T4NUKjRZ9FYCf8qCZJDG2ye7o4vJ6e7zNC7F/kNVS8Brwu+tosCdNDONCFz1iYJ7gU81+badtKkcgRQaMxgSNR+iWNIccmuIGWESnILMVvkt4JKBKoNYxeNF9iCdxMmCrEfwOLAn/d6M9tVaNU+ayfl5kiRt8+uctZxC4c5W2atgXiLOJkm7fdpptWPgcSZ4BqhIkxWO9RkKs5x5qgyV/Zfm8hQH4fFVB+RUFow8RQvpvFUEiRkGNAjw9yLlG9yhgRIze/aPPteMxXtmPd4iw1PGJZH6QnNVQ46rketG9AVXsK6vqBvs1HrrRQryeLK/BLeDfqinjGauWDPg0SDVeDSop9qxgfCBSBijPyJ8ozwXK3l80uxW1lP2xQaWVtEC82TSett5k5ydOR+kH8ZGNTfNpUZRQGwYROUhaBnwmTgUKsaZdqlnXx7VkpueR2SEQU3X03RkjPHic5Pmze3+TlI1YBX9dHnnapGvGvDpdvPXKk3z7p/iugHYB9WNIWsT39/e1Sn30g9rtNNjrlQh38XxarWK5kQ2JTG7FM3QC+F3LlZ/HbmX27vqZipKekp9Wl1/+1XJ9bS9dr8f2rNu1297Y2sMhRoOqEUFZm/4HFwen8h/G1ZvaQ9fEMRfmE1zSRQV3FfDo6dWxcPuAFNXfoUGEF9mM1rzhaTWl2lcfZ3pNdK4/DLTa/wGDrHqLQ==
NM0f9Kkps5TPmZw8
Listen
